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Abstract
In heterologous expression systems, human GnRH receptors
(hGnRHRs)arepoorlyexpressedatthecellsurfaceandthismay
reﬂectinefﬁcientexitfromtheendoplasmicreticulum.Here,we
havedeﬁnedtheproportionofGnRHRsatthecellsurfaceusing
a novel assay based on adenoviral transduction with epitope-
tagged GnRHRs followed by staining and semi-automated
imaging. We ﬁnd that in MCF7 (breast cancer) cells, the
proportional cell surface expression (PCSE) of hGnRHRs is
remarkablylow(!1%),whencomparedwithXenopuslaevis(X)
GnRHRs (w40%). This distinction is retained at comparable
whole cell expression levels, and the hGnRHR PCSE is
increasedbyadditionoftheXGnRHRC-tail(h.XGnRHR)or
by a membrane-permeant pharmacological chaperone (IN3).
The IN3 effect is concentration- and time-dependent and
IN3 also enhances the hGnRHR-mediated (but not
h.XGnRHR- or mouse GnRHR-mediated) stimulation of
[
3H]inositol phosphate accumulation and the hGnRHR-
mediated reduction in cell number. We also ﬁnd that the
PCSE for hGnRHRs and h.XGnRHRs is low and is greatly
increasedbyIN3intwohormone-dependentcancerlines,butis
higherandlesssensitivetoIN3inagonadotropeline.Finally,we
showthattheeffectofIN3onhGnRHRPCSEisnotmimicked
orblockedbytwopeptideantagonistsalthoughtheydoincrease
the PCSE for h.XGnRHRs, revealing that an antagonist-
occupiedcellsurfaceGnRHRconformationcandifferfromthat
of the unoccupied receptor. The low PCSE of hGnRHRs and
this novel peptide antagonist effect may be important for
understanding GnRHR function in extrapituitary sites.
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Introduction
Genetic disease can result from mutations that impair protein
trafﬁcking by causing misfolding and failure to meet quality
control for exit of newly synthesized protein from the
endoplasmic reticulum (ER; Kopito & Ron 2000). One of
the key advances in this ﬁeld has been the development
of pharmacological chaperones that stabilize protein confor-
mations that are more efﬁciently trafﬁcked. In the case of seven
transmembrane(7TM)receptors,atleasttendiseasesarelinkedto
mutationswithinthereceptorthatcauseretentionintheER.For
atleastthreeofthesereceptors,pharmacologicalchaperoneshave
been found that may increase ER exit and thereby increase
trafﬁcking to the plasma membrane (PM; Bernier et al.2 0 0 4 ).
There is also increasing evidence that a large proportion of
normal(non-mutated)proteinsalsofailtoexittheER.Indeed,it
appears that only 40% of newly synthesized human dopioid
receptor is actually transported to the PM in human embryonic
kindney (HEK)-293 cells (Petaja-Repo et al.2 0 0 2 ). The
receptors that fail to exit the ER are instead ubiquitinated and
targeted to the proteosome, while membrane-permeant ligands
(agonists and antagonists) increase the proportion of receptors
trafﬁckedtothePM(Petaja-Repoetal.2002).Accordingly,there
is considerable interest in the possibility that pharmacological
chaperones may have therapeutic beneﬁt in manipulation of
wild-type 7TM receptors, as well as in treatment of congenital
diseases of 7TM receptor trafﬁcking.
Gonadotropin-releasing hormone I (pGlu-His-Trp-Ser-
Tyr-Gly-Leu-Arg-Pro-Gly-NH2, GnRH-I) acts via Gaq-
coupled 7TM receptors to stimulate phospholipase C (PLC).
TheconsequentmobilizationofCa
2Candactivationofprotein
kinase C isozymes mediates secretion of luteinizing hormone
and follicle-stimulating hormone (Conn et al.1 9 8 7 , Stojilkovic
&Catt1995,Millaretal.2004).MostvertebratesexpressGnRH
II ([His
5,T r p
7,T y r
8]GnRH) along with one or more related
peptide. These forms of GnRH have apparently evolved in
parallel with distinct forms of the GnRHR (Millar et al.2 0 0 4 ).
The best-characterized GnRHRs (mammalian type I
GnRHRs) are selective for GnRH I. They include all known
mammalianGnRHRsexceptforthetypeIIGnRHRsrecently
describedinsomeprimatesand,unlikeallother7TMreceptors,
lack C-terminal tails. In contrast, non-mammalian GnRHRs
have higher afﬁnity for GnRH II than for GnRH I and have
C-tailsofvaryinglength(Millaretal.2004).Thesestructuresare
thought to be involved in receptor desensitization and
internalization (Pawson et al.1 9 9 8 , Blomenrohr et al.1 9 9 9 ,
McArdle et al.2 0 0 2 , Millar et al.2 0 0 4 ) and may also inﬂuence
receptor expression (below).
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unknown, cell surface human (h)GnRHR expression is
typically low in heterologous systems (compared with other
GnRHRs) due to speciﬁc structural features. For example, a
primate GnRHR-speciﬁc Lys191 may reduce GnRHRs
expression by destabilizing a cysteine bridge that is needed for
ER exit (Janovick et al. 2003, Ulloa-Aguirre et al. 2004,
Sedgley et al. 2006). Glycosylation can also inﬂuence
expression because the mouse GnRHR has glycosylation
sites at Asn4 and Asn18 within the amino-terminal sequence
and is expressed at higher levels than hGnRHR (which has
only the Asn18 site). hGnRHR expression is increased by
adding a second glycosylation site (Asn4), just as mGnRHR
expression is reduced by removal of Asn18 (Davidson et al.
1995, 1996, Sedgley et al. 2006). The absence or the presence
of C-tails can also inﬂuence expression, as addition of the
catﬁsh GnRHR C-tail to the rat GnRHR or addition of the
Xenopus (X)GnRHR C-tail to the human or sheep
(s)GnRHRs increases cell surface receptors (Lin et al. 1998,
Finch et al. 2004, Caunt et al. 2006). Although the ways in
which these structures inﬂuence expression are largely
unknown, the importance of trafﬁcking has been illustrated
by GnRHR point mutants that cause infertility, apparently by
misrouting otherwise functional receptors. Here, a key
observation is that a membrane-permeant GnRHR antagon-
ist (IN3) facilitates signaling via several of these mutant
hGnRHRs (Janovick et al. 2002, 2003, 2006, Brothers et al.
2004, Ulloa-Aguirre et al. 2004, Knollman et al. 2005,
Sedgley et al. 2006). This antagonist is thought to act as a
pharmacological chaperone, enabling the protein to fold
appropriately for ER exit, and thereby overcoming the
inhibitory effect of the mutations. The IN3 also caused a
modest increase in [
3H]IP accumulation mediated by the
wild-type GnRHR, and it was suggested that as much as 50%
of the hGnRHR does not trafﬁc to the PM in COS7 cells
(Brothers et al. 2004). Indeed, the inefﬁcient trafﬁcking of
wild-type hGnRHRs may predispose them to inhibitory
effects of mutations that further impair trafﬁcking (Janovick
et al. 2002, 2003, Brothers et al. 2004, Ulloa-Aguirre et al.
2004, Knollman et al. 2005).
GnRH-stimulated gonadotropin secretion can be blocked
with antagonists or mimicked byagonists, but in the latter case,
sustained stimulation causes desensitization. Thus, both
treatments ultimatelyreducecirculatinglevelsofgonadotropins
and gonadal steroids, causing the ‘medical castration’ that
underlies the use of GnRH analogs to treat steroid hormone-
dependent neoplasms such as those of the prostate, ovary,
endometrium, or mammary (Schally 1999). In addition to
expression in the pituitary, GnRHRs are found (often along
withGnRH)inmanycancersofreproductivetissues(Cheng&
Leung 2005). Interest in these extrapituitary GnRHRs stems
primarily from the fact that GnRH analogs (or their cytotoxic
derivatives) can inhibit proliferation of cell lines derived from
such cancers, and that direct anti-proliferative effects may
thereforecontributetothetherapeuticeffectsofGnRHanalogs
in cancer treatment (Eidne et al.1 9 8 7 , Kakar et al.1 9 9 4 , Imai
etal.1997,Emonsetal.1998,Schally&Nagy1999,Everestetal.
2001, Limonta et al.2 0 0 3 , Moretti et al.2 0 0 3 ,C h e n g&L e u n g
2005). In recent studies exploring the context dependence of
GnRHRsignaling,wehaveusedrecombinantadenovirus(Ad)
to express GnRHRs in hormone-dependent cancer cells that
lackendogenousGnRHRs(asjudgedbywholecellradioligand
binding and [
3H]IP accumulation experiments). In MCF7
breast cancer cells (for example), transduction with Ad
sGnRHR caused expression of high-afﬁnity Gaq-coupled
receptors that mediated a potent antiproliferative effect of
GnRH agonists (Everest et al.2 0 0 1 , Finch et al.2 0 0 4 ).
Antiproliferative effects in Ad hGnRHR-infected cells were
consistently lower than those in Ad sGnRHR-infected cells,
correspondingtolowercellsurfaceexpressionofthehGnRHR,
and we speculated that inefﬁcient delivery to the PM might be
an important determinant of hGnRHR function in hormone-
dependentcancercells(18).Here,wedescribeanovelsystemfor
GnRHR quantiﬁcation based on semi-automated acquisition
and analysis of digital ﬂuorescence images of N-terminal
HA-tagged GnRHRs at the cell surface and within cells.
Using this, we have determined the proportion of GnRHRs at
the cell surface. We show that the proportion of HA-tagged
hGnRHRs at the cell surface is remarkably low in hormone-
dependent cancer cell lines (!1%) and that the proportion of
GnRHRs can be increased by both peptide and non-peptide
antagonists, observations that may be important for therapeutic
use of such compounds.
Materials and Methods
Materials
PeptideswerefromSigmaexceptforBuserelin([T-BuSer
6,Pro
9
NHethylamide]GnRH)whichwasprovidedbyProf.JSandow
(Aventis Pharma GmbH, Frankfurt, Germany). Myo-
[2-
3H]inositol (10–25 Ci/mmol) was from NEN (Perkin–
Elmer, Boston, MA, USA). The membrane-permeant
GnRHR antagonist, IN3 ((2S)-2-[5-[2-(2-axabicyclo[2.2.2]-
oct-2-yl)-1,1-dimethy-2-oxoethyl]-2-(3,5-dimethylphenyl)-
1H-indol-3-yl]-N-(2-pyridin-4-ylethyl)propan-1-amine), was
provided by Dr Ashton Wallace (Merck and Co. Inc). Culture
mediawerefromGibcoBRLandplasticwarewasfromCorning
(supplied by Appleton Woods, Birmingham, UK) or Nunc
(supplied by Fisher, Loughborough, UK). Sera were from First
Link(Brierly Hill, UK) and antibodieswere fromInvitrogenor
Cambridge Biosciences (Cambridge, UK). cDNAs encoding
wild-type GnRHRswere provided by Prof. R Millar (Medical
Research Council Human Reproductive Sciences Unit,
Edinburgh, UK).
Engineering of receptors, cell culture, and transfection
Recombinant, E1 deleted Ad expressing hGnRHRs,
mGnRHRs, XGnRHRs, or h.XGnRHRs (chimeras consis-
tingofthehGnRHRwithanaddedXGnRHRC-terminaltail)
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et al. 2001, 2005, Franklin et al. 2003, Caunt et al. 2004, 2006).
For imaging, the Ad expressing the N-terminal HA-tagged
equivalents of these receptors were prepared as described
(Sedgleyetal.2006).MCF7andDU145cellsfromtheEuropean
Collection of Cell Cultures (Salisbury, UK) were routinely
culturedinDulbecco’smodiﬁedEagle’smedium(DMEM)with
10% fetal calf serum (FCS), 2 mM L-glutamine, 50 IU/ml
penicillin,and50 g/mlstreptomycin.For imagingexperiments,
they were plated in 96-well Corning Costar plates (Appleton
Woods) or Greiner Micro Clear plates (BioOne, Gloucester,
UK). For some experiments, the MCF7 cells were plated in
Greiner Micro Clear plates that had been pre-coated with
Matrigel basement membrane (BD Biosciences, supplied by
Biotrace Fred Baker Ltd, Runcorn, UK) following the
manufacturer’s instructions. LbT2 cells (gonadotrope lineage
cells provided by Prof. P Mellon, Universityof San Diego, CA,
USA)weremaintainedinserum-supplementedDMEM(Hislop
etal.2005)inMatrigel-coatedT75ﬂasks.Forexperiments,they
were plated (2500 cells/well) in Matrigel-treated Greiner Micro
Clear plates. GnRHRs were transiently expressed by infection
with Ad (6-h incubation, the day after plating) and assays were
then performed within 24 h of transduction. In the ﬁrst
experiments, (Fig. 1)A dt i t e r so f3 0 – 3 0 0p f u / n lw e r eu s e d .
Thereafter, titers giving comparablewholecellexpression levels
(300 pfu/nl for hGnRHRs, 100 pfu/nl for XGnRHRs and
h.XGnRHRs) were used throughout.
Quantiﬁcation of receptor expression by cell imaging
CellsurfaceandwholecellHA-GnRHRexpressionlevelswere
measured by ﬂuorescence microscopy using a semi-automated
system for image acquisition (IN Cell Analyzer 1000, GE
Healthcare UK Ltd, Little Chalfont, UK), and validated
algorithms for image segmentation and quantiﬁcation (IN Cell
Analyzer version 1.0 software). Brieﬂy, cells were cultured in
96-well plates at 2500–5000 cells/well, infected with Ad
HA-GnRHRs (as above) and left for 16–24 h prior to staining.
For cell surface receptor staining, they were incubated for 1 h at
4 8C with the primary antibody (mouse monoclonal anti-HA-
11, clone 16B12, stock at 5–7 mg/ml diluted 1:200 in DMEM
with1%BSA)andthenwashedwithice-coldPBS,ﬁxed(30 min
in 2% paraformaldehyde/PBS) then permeabilized (10 min in
PBS/0.1% Triton X-100). The cells were then washed (3!),
blocked (1 h in PBS/0.1% Triton X-100/1% BSA), and
incubated 1 h with the secondary antibody (Alexa Fluor 488
conjugated goat anti-mouse IgG at 1:500 in PBS/01% Triton
X-100/1% BSA). They were then washed with PBS (2!),
incubated with 2 mM4 0,6-Diamidino-2-phenyindole (DAPI,
15 min), and washed (3!) before imaging. For whole cell
staining, cells were washed with PBS, ﬁxed, permeabilized, and
blocked as above before being exposed to the anti-HA primary
antibody. They were then washed with PBS (3!5m i n ) ,
incubated with Alexa Fluor 488 conjugated anti-mouse IgG
and DAPI. Digital images were acquired, collecting one to four
ﬁelds per well with a 10!objective (Plan Apochromat,
Figure 1 Relationship between Ad titer and receptor expression in Ad GnRHR-infected MCF7 cells. MCF7
cells infected with the indicated titers of Ad expressing N-terminal HA-tagged hGnRHRs, h.XGnRHRs, or
XGnRHRs were stained for cell surface receptors (incubation of intact cells with primaryantibody) and nuclei
(DAPI) or for whole cell receptor expression (permeabilization before primary antibody addition), prior to
image acquisition and analysis as described in the Materials and Methods. The upper ﬁgures show stain
intensity (arbitrary ﬂuorescence units, AFU) at the cell surface (open symbols) or throughout the cell (whole
cell, ﬁlled symbols) in the positive cells in a single representative experiment (meanGS.E.M., nZ4). The lower
panels showrepresentative images of HA-GnRHR stainingat the cell surfaceor throughout the whole cell and
are from cells infected with Ad hGnRHR at 300 pfu/nl, and Ad h.XGnRHR or Ad XGnRHR each at 100 pfu/nl
(as indicated). These images show !1% of the total area imaged to generate the graphs shown. Two-way
ANOVA revealed that Ad titer and permeabilization were statistically signiﬁcant variables (P!0.01) for each
receptor type.
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1000 cells (per well) in a total imaged area of 0.6–2.4m m
2.
These images were then segmented and quantiﬁed using the IN
Cell 1000 Analyzer software (Dual Area Analysis Algorithm
version 1.0 from GE Healthcare). After subtraction of back-
groundﬂuorescence(measuredincell-freeregions),thisanalysis
provided ﬂuorescence intensity in arbitrary ﬂuorescence units
(AFU) per cell and per well. As an alternative measure, we also
deﬁned the proportion of imaged cells expressing measurable
HA-GnRHRs (cells in which ﬂuorescence was O10% above
background)andcompoundedthesevalues(%Cvecells!AFU
in Cve cells) as an expression index. In most experiments,
the expression index obtained without permeabilization (cell
surface expression index) was then expressed as a percentage of
theexpressionindexobtainedwithpermeabilization(wholecell
expression index) to calculate the proportional cell surface
expression (PCSE). Non-speciﬁc labeling was negligible, with
these protocols as revealed by the low ﬂuorescence intensity in
controlcellsreceivingnoAd(Fig.1)orbyomissionofprimaryor
secondary antibody (not shown).
[
3H]Inositol phosphate (IP) accumulation
[
3H]IP accumulation was used as a measure of PLC activity in
cells labeled with [
3H]inositol and stimulated for 60 min with
varied concentrations of Buserelin in the presence of 10 mM
LiCl as described (Everest et al. 2001, Hislop et al. 2001,
Sedgley et al. 2006). To test for effects of IN3, this was either
included during the incubation with Buserelin (co-incu-
bation) or was added immediately after Ad transduction and
during the co-incubation (e.g. present during a 16-h
pre-treatment as well as the co-incubation).
Quantiﬁcation of nuclear stains by cell imaging
Cellimaging wasalsoused toassesseffects ofvarioustreatments
oncell number. To doso, cellswere plated atlow density(250–
500 cells/well) in 96-well plates, transduced with
HA-GnRHRs (as above), and then incubated for 16–24 h in
reducedserummedium(culturemediumasabovebutwithonly
2% FCS). Test compounds were then added and the cells were
incubated for a further 24 h before addition of Hoechst 33342
trihydrochloridetrihydrate(Hoechst,1.25 mg/mlﬁnalconcen-
tration)tostainnuclei.Digitalimageswerethenobtained(using
the 10! objective) and nuclei were deﬁned (as above). In
addition to cell number, this method provides information on
nuclear size, shape, and stain intensity that can be used to probe
population dynamics (Mukherji et al. 2006). Frequency
distributioncurvesofintegrated nuclear Hoechststainintensity
(mean ﬂuorescence!nuclear area) showed the characteristic
biphasic distribution withdistinct 2nand4npeaks (e.g. G1/G0
and G2/S cells respectively) as well as cells with less intense
nuclear staining. In preliminary experiments, we found no
measurable effect of our test compounds on the 2n or 4n
populationsbuttheproportionofcellswithlownuclearstaining
was regulated. Accordingly, we deﬁned a sub-2n (putative
apoptotic) population as cells in which the integrated nuclear
stain intensity was !50% of the value for the 2n peak. As a
measureofproliferation,wealsodeﬁned theproportionofcells
with small and intensely stained anaphase nuclei (that were
characteristically seen in pairs) and used this as a mitotic index.
These nuclei were classiﬁed with a user-deﬁned training cell
population and software-deﬁned discrimination parameters
(nuclear area, integrated nuclear stain intensity, and the
coefﬁcient of variance of stain intensity within the nucleus)
using the Supervised Classiﬁer option of the IN Cell 1000
Analyzer software. In this way, we used the nuclear stain to
generate indices of apoptosis and mitosis in parallel with cell
numbers.
Statistical analysis and data presentation
The ﬁgures show the data (meanGS.E.M.) of three or four wells
in single experiments that are representative of at least two
similar experiments, or show data pooled from at least three
independent experiments. For pooling [
3H]IP accumulation,
data were normalized to the maximal response to Buserelin in
control cells. Statistical analysis was by two-way ANOVA and
Student’s t-test, accepting P!0.05 as statistically signiﬁcant.
Results
Imaging of epitope-tagged GnRHRs in MCF7 cells
The initial aim of these experiments was to develop an efﬁcient
means of deﬁning the proportion of GnRHRs at the cell
surface. To do so, we expressed N-terminal HA-tagged human
(h) and Xenopus laevis (X) GnRHRs and a chimeric receptor
consisting of the hGnRHR sequence in tandem with the
C-terminaltailoftheXGnRHR(h.XGnRH)inMCF7cellsby
infection with recombinant Adenovirus (Ad). Cell surface and
whole cell receptor expression was then determined by
ﬂuorescencemicroscopyfollowedbysemi-automatedimaging.
The HA-GnRHR staining was used to determine the
proportion of cells that were positively stained (ﬂuorescence
O10%abovebackground)andthestainintensityinthepositive
cells (arbitrary ﬂuorescence units, AFU). As expected,
increasing Ad titer caused an increase in whole cell receptor
expression as judged by increased AFU in the positively stained
cellsforallthreereceptors(Fig.1),andstainspeciﬁcityisevident
from the lack of staining in cells without HA-GnRHRs. The
titer-dependentincreaseinstainingwasparalleledbyanincrease
in the proportion of cells that were positively stained (below).
IncreasingAdXGnRHRtiteralsocausedaclear increaseincell
surface receptor expression as judged by both AFU in positive
cells (Fig. 1) and the proportion of cells that were positively
stained (not shown) but cell surface expressionwas much lower
(by either measure) in cells infected with Ad hGnRHR or Ad
h.XGnRHR (Fig. 1).
These data suggest that the proportion of XGnRHRs at the
cell surface is much greater than that for the hGnRHR or
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might inﬂuence this distribution. To address this, we infected
cellswithAdtitersselectedforcomparablewholecellexpression
(Ad hGnRHRat 300 pfu/nl,Adh.XGnRHR and XGnRHR
at 100 pfu/nl) and, in order to determine the inﬂuence of the
molecular chaperone, cells were cultured for 16 h in the
presenceor theabsenceofIN3(1.8!10
K8 M)beforestaining.
Intheseexperiments,wedeﬁnedtheproportionofcellsthatare
positively stained as well as the stain intensity in these cells, and
then calculated an ‘expression index’ by compounding these
values. Here, our intention was to mirror the situation in
conventional cellular binding assays (where receptor binding
reﬂects both the proportion of cells expressing the receptor and
theexpressionlevelwithinthosecells)andrepresentativeimages
are shown (Fig. 2 lower panel) to illustrate the image
segmentation and identiﬁcation of positively stained cells. Cell
surface and whole cell expression indices were then used to
determine the proportion of receptors at the cells surface
(PCSE). As shown in Fig. 2, cell surface expression of
h.XGnRHRs was slightly greater than that of hGnRHRs (as
judged by %Cve, AFU or by the expression index) and whole
cellvalueswerecomparable(byallthreeparameters).ThePCSE
for hGnRHRs was very low (0.34%) and was increased 7.0G
1.8-fold by IN3 (Fig. 2F). The PCSE for h.XGnRHRs was a
little higher (0.64%) and was increased 15.1G1.2-fold by IN3.
The PCSE for XGnRHRs was much greater than that of the
othertworeceptorsandwasunalteredbyIN3(below).IN3also
tendedtoincreasewholecellexpressionlevelsofbothreceptors
Figure 2 GnRHR localization atmatchedwholecellexpression levels. MCF7 cellsweretreated asdescribed for
Fig. 1exceptthattheywereincubatedfor16 hwith0(openbars)or1.8!10
K7 MIN3(ﬁlledbars)beforestaining
forHA-taggedreceptorsinintact(cellsurface)andpermeabilized(wholecell)cellsasindicated.Theﬁgureshows
the proportion of cells with cell surface staining (%Cve, panel A), the cell surface staining in those cells (AFU,
panelB),andtheexpressionindexcalculatedbycompoundingthesevalues(panelC).Fluorescenceintensityand
expression index were also determined for whole cell staining (panels D and E respectively) and used for
calculationofthe proportionofreceptorsatthecellsurface(proportional cell surface expression,PCSE, panelF).
These data are from the experiment shown in Fig. 1 (meanGS.E.M., nZ4) with Ad titers selected for comparable
wholecellexpression levels(300 pfu/nlfor AdhGnRHRand100 pfu/nlfor Adh.XGnRHR).Parallelexperiments
withtheXGnRHR(100 pfu/nl)yieldedPCSEvaluesof39.1G5.9an d59.1G25.6incontrolandIN3-treatedcells
respectively.Two-wayANOVAsofthegrapheddatarevealedIN3asasigniﬁcantvariableforeachmeasureexcept
for AFU in whole cells (e.g., P!0.05 for panels A–C, and F, but not for panel D). The lower panel images show
representative views of DAPI-stained nuclei and HA-GnRHR expressing cells as well as merged images.
Segmentation is also shown (lower right) to illustrate how the individual cells were ﬁltered to identify HA-GnRH
positivecells(greenoutlines,AFUO10%abovebackground)andnegativecells(redoutlines,AFU!10%above
background). Full colour version of this ﬁgure available via http://dx.doi.org/10.1677/JOE-07-0471.T h e
horizontal scale bar (DAPI image) is w20 mm.
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thewholeseriesofexperiments(notshown).Itsmajoreffectwas
to increase the proportion of hGnRHRs and h.XGnRHRs at
the cell surface and thereby increase cell surface expression.
Pooling data from the entire data series revealed control PCSE
values of 0.6G0.1, 1.4G0.5, and 39.1G5.6% (for the
hGnRHR, h.XGnRHR, and XGnRHR respectively) and
IN3-treated PCSE values of 6.1G0.6, 12.8G1.7,
and 45.9G9.8 (again, for the hGnRHR, h.XGnRHR, and
XGnRHR respectively).
Wenextexploredtheconcentrationandtimedependenceof
the IN3 effects on cell surface expression of the hGnRHR and
h.XGnRHR. As shown in Fig. 3, the IN3 effects were time
dependent, reaching maxima between 8 and 24 h, and changes
in the cell surface expression index were paralleled by changes
intheproportionofreceptorsatthecellsurface.TheIN3effects
on cell surface expression of these receptors were also
concentration dependent (Fig. 4)w i t h5 0 %e f f e c t i v ec o n c e n -
tration (EC50)v a l u e so f3 – 5 !10
K8 M for both receptors.
Although kinetics and concentration dependencies were
indistinguishable, maximal cell surface receptor expression
levels were consistently greater with the h.XGnRHR than
with the hGnRHR (Figs 3 and 4).
Context-dependence of GnRHR expression
We have suggested that the proportion of hGnRHRs
expressed at the cell surface may be dependent upon the
cell type (Sedgley et al. 2006), and have explored this using
our imaging assay in MCF7 breast cancer cells and DU145
prostate cancer cells. As shown in Fig. 5, expression data were
comparable in these cell lines. In both lines, the PCSE was
low (!1%) for the hGnRHR and a little higher (1–2%) for
the h.XGnRHR. The IN3 signiﬁcantly increased PCSE
values without measurably inﬂuencing whole cell expression
(not shown) so that qualitatively similardatawereobtained for
the cell surface expression index and the PCSE values (Fig. 5).
We next compared expression in MCF7 and LbT2
(gonadotrope lineage) cells. In preliminary experiments, we
found it necessary to use Matrigel-coated plates for the LbT2
cells (because they washed off uncoated plates) and therefore
included MCF7 cells on uncoated and Matrigel-coated plates
for comparison. As expected, the PCSE values were relatively
low for the hGnRHR and h.XGnRHR in MCF7 cells and
were signiﬁcantly increased by pre-incubation with IN3,
irrespectiveof the Matrigel treatmentofthe plates. Expression
levels were considerably higher for both receptors in the
gonadotrope lineage cells (5.1G1.8 and 11.5G2.6% for the
Figure 3 Time dependence of the IN3 effect on plasma membrane expression of HA-GnRHRs. MCF7 cells
infected with Ad HA-hGnRHRs (upper panels) or Ad HA-h.XGnRHRs (lower panels), incubated for the
indicated time with 0 (open circles) or 1.8!10
K7 M (ﬁlled circles) IN3 prior to staining and imaging as
described under Fig. 2. The ﬁgure shows expression indices (left panels) and the PCSE values (right panels)
pooled from four separate experiments (meanGS.E.M., nZ4) each with quadruplicate observations. Two-way
ANOVA revealed time and IN3 as signiﬁcant variables for each panel (P!0.01). IN3 effects were statistically
signiﬁcant (*P!0.05, **P!0.01 using Student’s t-test) compared with time-matched controls, as indicated.
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IN3 were much less pronounced. Thus, IN3 increased the
PCSE for hGnRHRs and h.XGnRHRs by 18.4G4.1- and
7.0G1.1-fold respectively in MCF7 cells but caused only
2.7G0.4- and 1.7G0.1-fold increases (respectively) in
expression of the same receptors in LbT2 cells (Fig. 6).
Effects of IN3 on GnRHR function
We next explored possible functional correlates of the MCF7
cell imaging data, using non-tagged GnRHRs. To do so, we
determinedtheeffectofIN3on[
3H]IPaccumulationmediated
by the hGnRHR, h.XGnRHR, or mouse (m) GnRHR. As
showninFig. 7, Buserelin caused arobust increaseof[
3H]IP by
activation of all three receptors and when co-incubated with
Buserelin, IN3 (1.8!10
K7 M) behaved as a competitive
antagonist, shifting the Buserelin concentration–response
curve rightward (e.g., increasing the EC50 from !1p Mt o
O10 nMatthehGnRHR).Whencellswerepre-incubatedfor
16 h with 1.8!10
K7 M IN3 (and the same concentration of
IN3 was maintained throughout the stimulation with Buser-
elin), this inhibited the response to lower concentrations of
Buserelin but actually increased the response to the higher
Figure 4 Concentration dependence of the IN3 effect on plasma
membrane expressionof HA-GnRHRs. MCF7cellswere transduced
with Ad HA-GnRHRs and incubated for 16 h with the indicated
concentration of IN3 prior to staining and imaging. Data shown are
cell surface expression indices from a representative experiment.
Two-way ANOVA revealed receptor type and concentration as
signiﬁcant variables (P!0.01) and IN3 signiﬁcantly increased cell
surface GnRHR expression as indicated (*P!0.05, **P!0.01 by
Student’s t-test).
Figure 5 Effects of IN3 on plasma membrane expression of HA-GnRHRs in MCF7 and DU145 cells. MCF7
(upper panels) and DU145 (lower panels) cells infected with Ad expressing the indicated GnRHRs and
incubated for 16 h in medium with 0 (ctrl., open bars) or 1.8!10
K7 M IN3 (ﬁlled bars) before imaging of cell
surface and whole cell receptors. The left panels show expression indices and the right panels show PCSE
values, pooled from four separate experiments each with three or four replicates (meanGS.E.M., nZ4). Two-
way ANOVAs revealed IN3 as a signiﬁcant variable (P!0.05) for each receptor and each endpoint, and the
effects of IN3 on PCSE were statistically signiﬁcant (*P!0.05, **P!0.01 when compared with control values
matched for cell and receptor type) for both receptors and both cell types.
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completely wash IN3 pre-treatments from cells, so the effect of
thepre-treatmentwascalculatedbysubtractionoftheresponses
obtained in cells co-incubated with IN3 and Buserelin, from
responses obtained in cells pre- and co-incubated with IN3.
Sincetheseresponsesaremeasuredunderconditionsofidentical
proportional receptor occupancy, this difference represents the
increased response due to the pre-treatment with IN3 and as
expected the IN3 pre-treatment caused a pronounced increase
in the hGnRHR-mediated response (Fig. 7D, see also Sedgley
et al.2 0 0 6 ). Interestingly, the IN3 pre-treatment did not
measurablyincreasetheresponsesmediatedbytheh.XGnRHR
or mGnRHR (Fig. 7B–D), implying that sufﬁcient number of
these receptors are present at the cell surface for maximal
activation even without IN3.
Since GnRH agonists can inhibit proliferation and/or
stimulate apoptosis in hormone-dependent cancer cell lines,
we also used automated imaging and analysis of Hoechst-
33342 stained nuclei to explore possible effects of Buserelin
and IN3 on cell number. As shown in Fig. 8A, IN3 and
Buserelin had no effect on cell number in control cells, but
after infection with Ad hGnRHR, Buserelin caused a
pronounced reduction in cell number and an even greater
reduction was seen with Buserelin in the presence of IN3.
Pooling data from three separate experiments revealed that
IN3 had no measurable effect in Ad hGnRHR-infected cells,
but the reduction in cell number caused by Buserelin was
signiﬁcantly greater in the presence of IN3 (P!0.05, data not
shown). Similar experiments were performed with cells
infected with Ad h.XGnRHRs and Ad mGnRHRs (not
shown) and ANOVAs with data pooled from three separate
experiments revealed Buserelin as a signiﬁcant variable for all
three receptors, whereas IN3 was only signiﬁcant for the
hGnRHRs (not shown). Frequency distribution curves of
Hoechst stain intensity revealed a characteristic biphasic
distribution with 2n and 4n peaks, enabling us to deﬁne the
proportion of cells with very low nuclear staining (integrated
nuclear stain !50% of the 2n peak value, Fig. 8B, inset). This
apoptotic index was unaltered by IN3 or Buserelin in control
cells but after infection with Ad hGnRHR, Buserelin caused
a pronounced increase in the sub-2n cells and an even greater
increase was seen with Buserelin in the presence of IN3
(Fig. 8B). We also calculated a mitotic index, as the
proportion of cells with small and densely stained nuclei
(post-mitotic cells). This was unaltered by IN3 or Buserelin in
control cells but after infection with Ad hGnRHR, Buserelin
caused a pronounced reduction in the proportion of these
post mitotic cells and an even greater reduction was seen with
Buserelin in the presence of IN3 (Fig. 8C and D). Thus, IN3
ampliﬁes the hGnRHR-mediated reduction in cell number,
and this effect is paralleled by a reduction in the proportion of
post-mitotic cells and an increase in the proportion of
apoptotic cells.
Comparison of peptide and non-peptide antagonists
In the ﬁnal series of experiments, we assessed whether
peptideligandscouldinﬂuencecellsurfaceGnRHRexpression
in MCF7 cells. As expected, the membrane-permeant
Figure 6 Effects of IN3 on plasma membrane expression of
HA-GnRHRs in MCF7 and LbT2 cells. LbT2 cells were cultured in
plates that had been pretreated with Matrigel and MCF7 cells were
either on Matrigel-treated plates (lower panel) or untreated plates
(middle panel). The cells were infected with Ad expressing
HA-tagged GnRHRs and then incubated for 16 h in medium with 0
(control) or 1.8!10
K7 M IN3, as indicated, before imaging. The
ﬁgure shows PCSE values pooled from seven separate experiments
each with four replicates (meanGS.E.M., nZ4–7). ANOVAs
revealed IN3 as a signiﬁcant variable (P!0.01) and the effects of
IN3 were statistically signiﬁcant (*P!0.05, **P!0.01 when
compared with control values for matched cell and receptor type)
for both receptors and both cell types.
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PCSE for the hGnRHR, and no such effect was seen with two
peptideantagonists(antideandcetrorelix).TheIN3alsocaused
the expected increase in PCSE for the h.XGnRHR and
the GnRH had no measurable effect on either receptor.
Surprisingly, however, both antide and cetrorelix increased the
proportion of h.XGnRHRs at the cell surface (Fig. 9). These
effects were relatively modest (compared with IN3 effects) and
occurred without any measurable change in whole cell
expression level, so that the effects on PCSE were mirrored by
increasesinthecellsurfaceexpressionindex(Fig.9,anddatanot
shown). The effects of these peptides on cell surface expression
of h.XGnRHRs were time dependent (maximal at 24–48 h)
andconcentrationdependent(EC50w10
K8M)andwhenIN3
and the peptides were co-incubated, no functional interaction
occurred (Fig. 10 and data not shown).
Discussion
When hGnRHRs are heterologously expressed, cell surface
receptornumbersarelowcomparedwithotherGnRHRs(e.g.,
type I rodent or ovine GnRHRs and type II Xenopus (X) or
catﬁsh GnRHRs; Davidson et al.1 9 9 5 , Janovick et al.2 0 0 3 ,
Ulloa-Aguirreetal.2004,Sedgleyetal.2006).Thiscouldreﬂect
differences in receptor synthesis and degradation inﬂuencing
whole cell expression, or differences in trafﬁcking affecting the
proportion at the PM. Without reliable antibodies or
PM-permeant radioligands, it has not been possible to deﬁne
the proportion of endogenous GnRHRs at the cell surface but
thiscanbeexploredwithtaggedGnRHRs.Toourknowledge,
the proportion of human or non-mammalian GnRHRs at the
cell surface has not previously been determined; therefore, our
initial aim was to develop an efﬁcient means of doing so. Here,
Figure 7 Effect of IN3 on GnRHR-mediated [
3H]IP responses. MCF7 cells were infected with Ad expressing
hGnRHR,h.XGnRHR,ormGnRHRandthentransferredtomediawith0or1.8!10
K7 MIN3and[
3H]inositol(for
16 h),thenwashedandstimulatedfor1 hwiththeindicatedconcentrationofBuserelinwith10 mMLiClandeither
0 (control) or 1.8!10
K7 M IN3. Panels A–C show data for cells receiving no IN3 (control), as well as for cells
receiving IN3 during the stimulation with Buserelin (co-incubation) or during both the 16-h pretreatment and the
Buserelin stimulation (pre- and co-incubation) and these data are normalized as a percentage of the maximal
response to Buserelin in control cells (those receiving no IN3). These data are pooled from three separate
experimentseachwithtriplicateobservations(meanGS.E.M.,nZ2–3)andthecontrolvalueswere592G52,520G
101, and 1337G91 c.p.m./well (nZ3) for the hGnRHR, h.XGnRHR, and mGnRHR respectively. Panel D shows
theincrementintheresponseduetotheIN3pre-incubation(e.g.,theresponseincellspre-treatedandco-incubated
withIN3minustheresponseincellreceivingIN3co-incubationalone)forallthreereceptors,andthedatainpanel
D are calculated from those in panels A–C. Maximal hGnRHR-mediated [
3H]IPaccumulation was signiﬁcantly
increased by pre- and co-incubation with IN3 (* P!0.05, panel A), whereas it caused no such increase in the
maximalh.XGnRHR-mediatedormGnRHR-mediatedresponses(panelsBandC).Theeffectofpre-incubationwas
statisticallysigniﬁcantfor10
K10–10
K6 MBuserelinactingviathehGnRHR(**P!0.01,*P!0.05;panelD)butnot
for any concentration of Buserelin acting via the h.XGnRHR or mGnRHR (PO0.1, panel D).
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and a semi-automatic ﬂuorescence microscopy system to
quantify GnRHR expression in whole cells (permeabilized
before primary antibody addition) and at the cell surface (cells
permeabilizedafter primaryantibodyaddition).Wehavefound
that the proportion of HA-GnRHRs at the cell surface is
dependent upon receptor structure (it is much lower for the
HA-hGnRHR than the HA-XGnRHR and is increased by
additionoftheXGnRHRC-tailtotheHA-hGnRHR),canbe
manipulated pharmacologically (byaddition of the membrane-
permeant antagonist IN3), and is dependent upon cellular
context (the proportionof HA-hGnRHRsat the cell surface is
approximately ﬁve times greater in gonadotrope-linage LbT2
cells than in two hormone-dependent cancer cell lines). When
cellsurfaceexpressionandtheproportionofreceptorsatthecell
surface were both measured, these parameters invariably
changed in parallel. Thus, each of the experimental variables
inﬂuenced cell surface expression byaffectingthe proportionof
receptors at the cell surface (without any change in whole cell
receptor expression levels), revealing the importance of
compartmentalization as a determinant of cell surface
GnRHR number.
Cellular compartmentalization of GnRHRs
The ﬁnding that !1% of the HA-hGnRHR is resident at the
cell surface is consistent with earlier work where we imaged
HA-GnRHRsby confocal microscopyandfoundvery low cell
surface expression (Sedgley et al.2 0 0 6 ). However, it is not
possible to relate quantiﬁcation within a thin optical plane to
distribution throughout the cell and a key difference between
these approaches is that the wide-ﬁeld system used here has a
depth of ﬁeld of w6 mm, which is comparable with the cell
height (w5 mm, not shown). This quantiﬁcation therefore
approximatesstainingthroughoutthecellandthedatahereinare
equivalent to that obtained with confocal z-stack compression
but the semi-automated wide-ﬁeld system is much more rapid
anddoesnotinvolvethepotentialbiasofuser-deﬁnedregionsof
interest. Our data are also consistent with the work of Conn’s
group, who have shown that the pharmacological chaperone
IN3 increases hGnRHR-mediated [
3H]IP responses by 1.5- to
2-fold (using protocols with which the IN3 pre-treatment is
washed from the cell prior to agonist stimulation) and have
Figure 8 Effects of Buserelin and IN3 on cell number and nuclear
stains. Control and Ad hGnRHR infected cells were cultured in
medium with 2% FCS with or without Buserelin (10
K7 M) and IN3
(1.8!10
K7 M) as indicated, prior to staining and imaging to
determine cell number (in the imaged area of 2.4m m
2) as well as
the proportion of sub-2n and post-mitotic cells. The bar charts are
from a single representative experiment (meanGS.E.M., nZ4,
*P!0.05, **P!0.01 by Student’s t-test). Analysis of data pooled
from three similar experiments by two-way ANOVAs revealed that
Buserelin was not a signiﬁcant variable in control cells but was in
Ad hGnRHR-infected cells (P!0.01), and in Ad hGnRHR-infected
cells the reduction of cell number was greater in cells treated with
IN3 and Buserelin than in cells receiving Buserelin alone (P!0.05
by Student’s t-test). The inset in panel B shows a distribution proﬁle
with integrated nuclear stain intensity on the horizontal axis
(arbitrary ﬂuorescence units) and cell number (in thousands) on the
vertical axis, demonstrating the 2n and 4n cell populations and the
arbitrary cut-off (!50% of the 2n peak) used to deﬁne sub-2n cells.
Panel D shows a small proportion of the image captured from a
single well, illustrating the small and highly stained nuclei that were
characteristically seen in pairs and identiﬁed by the analysis
algorithmas post-mitotic (anaphase)cells(arrows).Horizontalscale
barZw20 mm.
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the PM predisposes them to effects of point mutations that
further impair trafﬁcking (Janovick et al. 2003, 2006,
Ulloa-Aguirre et al.2 0 0 4 ,Brothers et al. 2004, Knollman et al.
2005). They have suggested (Brothers etal.2 0 0 4 )t h a to n l y5 0 %
of the hGnRH is trafﬁcked to the PM, whereas our data reveal
!1% at the surface in MCF7 cells. We suspected that this
remarkably low PCSE was due to overexpression but this is
clearly not the case as we found a PCSE of !1% for the
HA-hGnRHR as compared with w40% for the XGnRHR
under conditions where whole cell expression levels are
indistinguishable (Fig. 2). Moreover, maximal cell surface
expression of hGnRHRs in this model is only 1–2000 sites
per cell (Finch et al. 2004), as compared with w80 000 sites per
cell for the endogenous mouse GnRHRs of aT3-1 cells
(McArdle et al. 1992). An alternative possibility is that the
N-terminal HA-tag may have inﬂuenced receptor function but
wehavefoundthatthesetagsdonotinﬂuenceafﬁnity,speciﬁcity,
cell surface expression levels, or potency in radioligand binding
and [
3H]IPaccumulation assays with any of the GnRHRs used
here (Sedgley et al.2 0 0 6 , and data not shown).
Effects of IN3 on GnRHR compartmentalization and function
In exploring functional correlates of IN3 effects on receptor
expression, we found that co-incubation with IN3 shifted the
concentration–response curve for Buserelin-stimulated
[
3H]IPaccumulation rightward (as expected for a competitive
antagonist) but also caused a modest increase in the maximal
response (presumably by increasing cell surface receptors). We
also constructed concentration–response curves in cells pre-
Figure 9 Effects of membrane-permeant and membrane-imper-
meant ligands on plasma membrane expression of HA-GnRHRs.
MCF7 cells were infected with Ad expressing HA-hGnRHRs (upper
panel)orh.XGnRHRs(lowerpanel)andthenincubatedfor16 hwith
control medium (ctrl.) or medium supplemented with IN3 (1.8!
10
K6 M), antide (ant.; 10
K8 M), cetrorelix (cet.; 10
K8 M), or GnRH
(G,10
K8 M)beforeimaging.ThedatashownarePCSEvaluespooled
from seven separate experiments each with three or four replicates
(meanGS.E.M., nZ4–7) and the effects of IN3 were statistically
signiﬁcant at both receptors, whereas the effects of antide and
cetrorelix were signiﬁcant only at the HA-h.XGnRHRs (*P!0.05,
**P!0.01 compared with control values for receptor type).
Figure 10 Time course of effects of membrane-permeant and
membrane-impermeant ligands on plasma membrane expression of
HA-h.XGnRHRs. Upper panel: MCF7 cells were cultured and
treated as described under Fig. 9, except that only the
HA-h.XGnRHR was used and incubation times were varied as
indicated. The data shown are expression indices pooled from four
separate experiments each with three replicates (meanGS.E.M.,
nZ4). Two-way ANOVA revealed that treatment and time were
both signiﬁcant variables (P!0.01) and the effects of all antagonists
were signiﬁcant (P!0.05 compared with time-matched controls) at
24 and 48 h. The effects of IN3 (but not cetrorelix or antide) were
also signiﬁcant (P!0.05) after 1 and 2 h of incubation. Lower
panels: MCF7 cells were cultured and transduced with Ad HA-
GnRHR or Ad h.XGnRHR and then incubated 16–24 h with or
without IN3 (1.8!10
K6 M) and cetrorelix (cet., 10
K8 M) before
staining and imaging.The data shown are pooled from four separate
experiments each with three replicates (meanGS.E.M., nZ4). Two-
way ANOVA revealed IN3 as a signiﬁcant variable at both receptors
and cetrorelix as a signiﬁcant variable at the HA-h.XGnRHRs
(P!0.01) but the IN3–cetrorelix interaction was not statistically
signiﬁcant at either receptor (PO0.05). *P!0.05, **P!0.01
compared with controls by Student’s t-test.
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in the continued presence of IN3 (Fig. 7), enabling the effect
of the pre-treatment to be determined. This revealed
profound effects of the chaperone. Thus, for example,
10
K8 M GnRH increased [
3H]IP accumulation by 10.6%
when co-incubated with IN3 and by 75.7% when pre- and
co-incubated with IN3. Since GnRHR-mediated [
3H]IP
accumulation responses are often used as measures of receptor
number, this sevenfold increase is indicative of a comparable
increase in cell surface receptors and supports the idea that the
vast majority of potentially functional hGnRHRs are
intracellular. In contrast, we found that the IN3 pre-
incubation did not enhance [
3H]IP responses mediated by
either the h.XGnRHR or the mGnRHR, presumably
because these receptors are sufﬁcient at the cell surface to
mediate maximal responses, even without IN3. In this regard,
we have shown that cell surface h.XGnRHR and mGnRHR
are considerably higher than for hGnRHRs (Sedgley et al.
2006) and considerable evidence suggests that the mGnRHR
is more efﬁciently trafﬁcked to the PM than the hGnRHR
(Davidson et al. 1996, Janovick et al. 2006). Importantly, these
experiments (Fig. 7) were performed with non-tagged
GnRHRs and therefore provide a functional correlate with
the imaging of HA-GnRHRs herein.
We also tested for effects on cell number as well as on
numbers of apoptotic and mitotic cells (Mukherji et al. 2006)
and found that Buserelin and IN3 had no effect on cell
number in control cells, whereas Buserelin (but not IN3)
reduced cell number in cells expressing hGnRHR,
h.XGnRHR, or mGnRHR (Fig. 8 and data not shown).
Importantly, the effect of Buserelin on cell number was
actually increased by IN3 and was paralleled by an increase in
the apoptotic index and a reduction in the mitotic index
(Fig. 8 and data not shown). Thus, the agonist apparently
reduces cell number by reducing proliferation and increasing
apoptosis and these effects are enhanced by IN3. Moreover,
we found that IN3 increased the hGnRHR-mediated effect
on cell number but did not increase the h.XGnRHR- or
mGnRHR-mediated effects (not shown), consistent with the
[
3H]IP accumulation data (Fig. 7D) and the notion that these
are sufﬁcient at the surface to mediate maximal effects even
without IN3. Thus, this antagonist can actually be used to
amplify GnRHR-mediated effects, butonly when cell surface
receptor number is sufﬁciently small to be rate limiting for the
observed response.
GnRHR compartmentalization in gonadotrope and hormone-
dependent cancer cell lines
We also explored the cell context dependence of GnRHR
compartmentalization (Figs 5 and 6) and found that PCSE
was low (e.g., !1% for the HA-hGnRHR) and the effect of
IN3 was pronounced (e.g., HA-hGnRHR PCSE increased
7- to 18-fold by IN3) in two hormone-dependent cancer cell
lines (MCF7 and DU145). In contrast, PCSE was
considerably higher (e.g., w5% for the HA-hGnRHR) and
the effect of IN3 was less pronounced (e.g., HA-hGnRHR
PCSE increasedonly 1.5- to 3-fold byIN3) in LbT2cells. We
also considered the possibility that the endogenous
mGnRHRs in LbT2 cells might increase HA-hGnRHR
trafﬁcking to the cell surface, but we have found that
expression of untagged mGnRHRs does not inﬂuence the
PCSE of co-expressed HA-hGnRHRs (not shown), so these
data are unlikely to be inﬂuenced by functional interaction
between hGnRHRs and mGnRHRs. Thus, these experi-
ments clearly demonstrate that the proportion of hGnRHRs
resident at the cell surface of unstimulated cells varies
according to the cell type and suggest that cell surface
expression may be more efﬁcient in gonadotropes than in
hormone-dependent cancer cells.
Effects of peptide and non-peptide antagonists
Pharmacological chaperones are thought to bind receptors
within the ER, holding them in a conformation suitable for
ER exit. Keyevidence for this includes ER localization of the
receptor, dependence of the chaperone effect on ER to Golgi
transit, and the inability of peptide ligands to mimic effects of
the membrane-permeant pharmacological chaperone
(Kopito & Ron 2000, Bernier et al. 2004). In accord with
this, we have shown that HA-hGnRHR is largely co-loca-
lized with calreticulin (an ER marker) in MCF7 cells and
knockdown of calnexin (a molecular chaperone mediating
ER exit of many proteins) can reduce hGnRHR-mediated
[
3H]IP accumulation and radioligand binding to cell surface
hGnRHRs (Brothers et al. 2006). We also compared the
effects of IN3, with two peptide antagonists and as expected,
IN3 increased the HA-hGnRHR PCSE, whereas the
peptides had no such effect. The clear implication is that
IN3 increases HA-hGnRHR PCSE by binding nascent
receptors within the cell and that the peptides fail to do so
because they do not access these intracellular receptors. We
also found that these peptide antagonists failed to block the
effect of IN3 on HA-hGnRHR PCSE, again arguing that
they do not have access to the intracellular site at which IN3
acts. However, we were surprised to ﬁnd that the peptide
antagonists did increase PCSE of HA-h.XGnRHRs.
Although their effects were much less than that of IN3
(Fig. 9, lower panel), they were statistically signiﬁcant. This
difference in efﬁcacy was not due to difference in time courses
because effects of both IN3 and the peptide antagonists were
maximal at 24–48 h of incubation (Fig. 10), or to differences
in potency because maximally effective concentrations of
these peptides (10
K7 and 10
K8 M) were less effective than
IN3 (Figs 9 and 10, data not shown). Moreover, the effects
were antagonist speciﬁc because GnRH and Buserelin failed
to increase the PCSE of HA-h.XGnRHRs (Fig. 9, data not
shown). Theoretically, the GnRHR PCSE could be elevated
by increasing ER to PM trafﬁcking, by reducing interna-
lization from the PM, or by accelerating recycling of
A R FINCH and others . Intracellular human GnRHRs 364
Journal of Endocrinology (2008) 196, 353–367 www.endocrinology-journals.orginternalized receptors back to the PM. The IN3 effect is
largely (or entirely) attributable to the ﬁrst of these
mechanisms; however, since GnRH analogs are taken up by
receptor-mediated endocytosis and do not pass freely across
the PM (Scvatrz & Hazum 1987), and both peptides failed to
inhibit IN3 effects on HA-hGnRHR PCSE (Fig. 10), they
are unlikely to have access to GnRHRs within the ER. We
therefore suggest that the peptide antagonists could act at the
cell surface to slow internalization in the face of ongoing
trafﬁcking of the HA-h.XGnRHR to and from the PM. This
observation has important implications for GnRHR func-
tion. Conventional receptor theory assumes that there are
single inactive and active receptor conformations that are
induced or stabilized by antagonists and agonists respectively.
It is now clear, however, that there are multiple active
conformations for many 7TM receptors, including GnRHRs
(Caunt et al. 2004, Maudsley et al. 2004). The pharma-
cological chaperone effect of IN3 implies that there are also
distinct unoccupied and antagonist-occupied conformations
(the unoccupied hGnRHR conformation that fails to exit the
ER, and the IN3 occupied conformation that is trafﬁcked to
the cell surface). However, conformations within the ER
could presumably relate to protein maturation and would not
necessarily equate to multiple inactive conformations of the
mature receptor at the cell surface. Most importantly, the
effect of the peptide antagonists reveals the existence of an
antagonist-occupied GnRHR conformation at the cell
surface that differs from that of the unoccupied receptor
(e.g., that more than one functionally distinct GnRHR
conformation can exist at the cell surface that is inactive in
terms of PLC activation).
Possible relevance to GnRHR function in
hormone-dependent cancers
In addition to the pituitary, GnRHRs are found in many
cancers of reproductive tissues (Cheng & Leung 2005).
GnRH analogs can inhibit proliferation of cell lines derived
from such cancers and there is interest in the possibility that
direct anti-proliferative effects may contribute to the effects of
GnRH analogs in cancer treatment. However, this ﬁeld is
controversial as, for example, early work revealed direct
antiproliferative effects of GnRH agonists and GnRHRs on
MCF7 cells, whereas others have observed neither (Everest
et al. 2001). This could reﬂect the use of different sub-clones
in different laboratories. Indeed, the MCF7 and DU145 cells
used here lack endogenous GnRHRs as judged by
radioligand binding, [
3H]IP accumulation, and
[
3H]thymidine incorporation assays (Everest et al. 2001,
Franklin et al.2 0 0 3 ). Where found, the GnRHRs of
hormone-dependent cancers are often of lower afﬁnity
(Eidne et al. 1987, Emons et al. 1998, Schally 1999, Cheng
& Leung 2005) and may signal differently to those in the
pituitary. Typically, they fail to elicit the PLC activation
characteristic of pituitary GnRHRs (Emons et al. 1998,
Schally 1999, Cheng & Leung 2005) and the established
agonist/antagonist dichotomy may not be retained in cancer
cells, where compounds that act as antagonists at gonadotrope
GnRHRs can actually mimic agonist effects (Emons et al.
1998, Schally 1999, Cheng & Leung 2005). Such differences
occur in spite of the fact that the type I GnRHR transcripts in
breast and ovarian cancers are identical to those of the
pituitary (Kakar et al. 1994) and do not reﬂect activation of
type II GnRHR because a missense mutation and premature
stop codon prevent full length GnRHR expression from the
human type II GnRHR (pseudo)gene (Millar 2005). Our
data raise the possibility that compartmentalization may
underlie some of these differences. Thus, binding protocols
using crude PM preparations (and developed largely for work
with rodent tissues and cells) may be inappropriate for
detection of hGnRHRs that are primarily intracellular in
cancer cells. Similarly, effects on rapid responses such as Ca
2C
mobilization and [
3H]IP accumulation may be more readily
detected when a large proportion of GnRHRs are PM
resident (favoring detection of responses mediated by rodent
receptors in gonadotropes), whereas chronic effects on
proliferation may provide time for intracellular receptors to
trafﬁc to the surface for signaling (favoring detection of
responses mediated by hGnRHRs in cancer cells). Similarly,
the existence of functionally distinct peptide antagonist-
occupied and antagonist-unoccupied GnRHR confor-
mations is compatible with peptide antagonist signaling in
cancer cells. Although these issues are speculative, we suggest
that the low PCSE and existence of a large intracellular
reserve of potentially functional hGnRHRs may be
important for understanding of GnRHR signaling in
hormone-dependent cancer cells.
Agonist-induced receptor trafﬁcking
A further surprising observation was that GnRH did not
reduce the PCSE for hGnRHRs or h.XGnRHRs (Fig. 9)
because agonist-induced GnRHR internalization and the
consequent reduction in PM receptors are assumed to
contribute toward desensitization of GnRH-stimulated
gonadotropin secretion (Conn & Crowley 1994). However,
we have shown that equilibrium binding of [
125I]Buserelin to
cell surface hGnRHRs in MCF7 cells is extremely low and
that binding can be rapidly increased by raising the
temperature to 37 8C, suggesting the existence of cryptic
receptors that can move to the cell surface at temperatures
permissive for trafﬁcking (Sedgley et al. 2006). Since no such
temperature-dependent increase was seen with hGnRHRs
mutated to prevent G-protein-mediated signaling, we
suggested that the cell surface GnRHR activation may
stimulate recruitment from the cryptic receptor pool in this
model. Thus, the lackof GnRH effect on PCSE (Fig. 9) could
reﬂect concomitant agonist-induced recruitment to and
internalization from the PM. It is important to recognize,
however, that most of the early work on agonist-induced
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GnRHRs (Jennes et al. 1986, Conn et al. 1987, McArdle
et al. 1987, Schvartz & Hazum 1987, Hazum & Conn 1988)
which are now thought to be trafﬁcked to the PM
more efﬁciently than hGnRHRs (Janovick et al. 2003,
Ulloa-Aguirre et al.2 0 0 4 ). Moreover, one of the key
arguments for the occurrence of agonist-induced GnRHR
internalization is that internalization is faster for labeled
agonists than for labeled antagonists but the effect of antide
and cetrorelix on PCSE raises the possibility that these
antagonists could actually slow hGnRHR internalization. As
such, our observations highlight the need for more direct
assessment of agonist effects on internalization of hGnRHRs
in gonadotrope and extrapituitary cell types.
In summary, we have developed a rapid and efﬁcient means
of measuring GnRHR expression at the cell surface and
within cells and have used this to calculate, for the ﬁrst time,
the proportion of GnRHRs at the cell surface in hormone-
dependent cancer cells and in gonadotrope lineage cells. We
show that the proportion of HA-hGnRHRs at the cell
surface of MCF7 breast cancer cells is remarkably low (!1%)
when compared with the XGnRHR (w40%) even at
comparable whole cell expression levels, and that the PCSE
of the HA-hGnRHR can be increased by addition of the
XGnRHR C-tail and by stimulation with non-peptide
antagonists IN3. The IN3 effect is concentration- and time-
dependent and IN3 pretreatment increased expression of
functional hGnRHRs at the cell surface, as revealed by its
ability to increase hGnRHR-mediated (but not
h.XGnRHR- or mGnRHR-mediated) [
3H]IPx accumu-
lation and effects on cell number. In all of these experiments,
effects on cell surface GnRHR expression were paralleled by
changes in proportion of GnRHRs at the cell surface,
underlining the importance of compartmentalization as a
determinant of cell surface GnRHR number. Exploring
context dependence, we found that the proportion of
hGnRHRs and h.XGnRHRs at the cell surface is low and
is greatly increased by IN3 in two hormone-dependent
(breast- and prostate-derived) cancer lines but is considerably
higher and less sensitive to IN3 in a gonadotrope line. Finally,
we show that in MCF7 cells, the proportion of h.XGnRHRs
at the cell surface can also be increased by two (membrane
impermeant) peptide antagonists. This unexpected obser-
vation reveals the existence of an antagonist-occupied
conformation of a cell surface GnRHR that is functionally
distinct from that of the unoccupied receptor. The low
proportion of hGnRHRs at the cell surface and this novel
antagonist effect on cell surface receptor conformation and
number may be important parameters in understanding
GnRHR function in extrapituitary sites. Indeed, much of the
recent work on GnRHR trafﬁcking has focused on the
potential use of pharmacological chaperones to rescue
trafﬁcking deﬁcient hGnRHR point mutants, whereas our
data highlight the potential for peptide and non-peptide
antagonists to inﬂuence cell surface expression of wild-type
hGnRHRs in hormone-dependent cancers.
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